THE LYSO-PRECURSOR OF PLATELET-ACTIVATING-FACTOR (LYSO-PAF) IN ISCHEMIC MYOCARDIUM

被引:0
|
作者
LEONG, L
STURM, M
TAYLOR, R
机构
[1] ROYAL PERTH HOSP,DEPT CARDIOL,WELLINGTON ST,PERTH,WA 6000,AUSTRALIA
[2] UNIV WESTERN AUSTRALIA,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA
[3] UNIV WESTERN AUSTRALIA,DEPT CARDIOL,NEDLANDS,WA 6009,AUSTRALIA
来源
JOURNAL OF LIPID MEDIATORS | 1991年 / 4卷 / 03期
关键词
PLATELET-ACTIVATING FACTOR; LYSO-PHOSPHOLIPIDS; MYOCARDIAL ISCHEMIA; ARACHIDONIC ACID; PHOSPHOPLIPASE-A2;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
While it has been postulated that lyso-PAF and PAF might contribute to structural and functional damage in myocardial ischaemia, there has been no clear evidence for the accumulation of these bioactive compounds in ischaemic myocardium. In open chest, anaesthetised dogs, the proximal left anterior descending coronary artery was ligated and myocardial samples from the central ischaemic and normal areas assayed for lyso-PAF, free arachidonic acid and PLA2 activity. Ischaemic myocardium contained 50 +/- 29% (SD) more lyso-PAF than non-ischaemic myocardium after 20 min ischemia (P < 0.002; N = 8) and 53 +/- 39% more after 60 min (P < 0.01; N = 8) but there was no difference after 10 min (N = 8). Free arachidonic acid significantly increased in ischaemic myocardium after 60 min (122 +/- 136%; P < 0.05) while no increase in PLA2 activity was found in-vitro. Since lyso-phospholipids themselves damage cell membranes and, additionally, lyso-PAF is the precursor of PAF which has potent effects on platelets, leukocytes and small vessels, the increase in lyso-PAF in ischaemic myocardium could contribute to myocardial damage.
引用
收藏
页码:277 / 287
页数:11
相关论文
共 50 条
  • [21] Interdigitation of bilayers from ether lipid analogs: (R)-PAF, (R)-lyso-PAF and the antineoplastic (R)-ET-18-OMe
    Xie, XQ
    Lin, SY
    Moring, J
    Makriyannis, A
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1996, 1283 (01): : 111 - 118
  • [22] PLATELET-ACTIVATING-FACTOR (PAF)-INDUCED PLATELET-AGGREGATION - MODULATION BY PLASMA ADENOSINE AND METHYLXANTHINES
    AGARWAL, KC
    CLARKE, E
    ROUNDS, S
    PARKS, RE
    HUZOORAKBAR
    BIOCHEMICAL PHARMACOLOGY, 1994, 48 (10) : 1909 - 1916
  • [23] Enzymatic methods for choline-containing water soluble phospholipids based on fluorescence of choline oxidase: Application to lyso-PAF
    Sanz-Vicente, Isabel
    Dominguez, Andres
    Fernandez, Carlos
    Galban, Javier
    ANALYTICAL BIOCHEMISTRY, 2017, 519 : 30 - 37
  • [24] PLATELET-ACTIVATING-FACTOR AND THE CIRCULATION
    VANDONGEN, R
    JOURNAL OF HYPERTENSION, 1991, 9 (09) : 771 - 778
  • [25] PLATELET-ACTIVATING-FACTOR AND ISCHEMIA
    POTRON, G
    PETITFRERE, E
    NGUYEN, P
    CLINICAL HEMORHEOLOGY, 1993, 13 (02): : 155 - 176
  • [26] A COMPETITIVE RECEPTOR-BINDING ASSAY FOR PLATELET-ACTIVATING-FACTOR (PAF) - QUANTIFICATION OF PAF IN RAT-BRAIN
    TIBERGHIEN, C
    LAURENT, L
    JUNIER, MP
    DRAY, F
    JOURNAL OF LIPID MEDIATORS, 1991, 3 (03): : 249 - 266
  • [27] Role of platelet-activating-factor (PAF) on cellular responses after stimulation with leptospire lipopolysaccharide
    Isogai, E
    Hirose, K
    Kimura, K
    Hayashi, S
    Kubota, T
    Fujii, N
    Isogai, H
    MICROBIOLOGY AND IMMUNOLOGY, 1997, 41 (03) : 271 - 275
  • [28] PLATELET-ACTIVATING-FACTOR (PAF) CONCENTRATION AND PAF ACETYLHYDROLASE ACTIVITY IN CEREBROSPINAL-FLUID OF PATIENTS WITH SUBARACHNOID HEMORRHAGE
    HIRASHIMA, Y
    ENDO, S
    OHMORI, T
    KATO, R
    TAKAKU, A
    JOURNAL OF NEUROSURGERY, 1994, 80 (01) : 31 - 36
  • [29] PLATELET-ACTIVATING-FACTOR (PAF) HAS NO DIRECT EFFECT ON RAT INTRACEREBRAL ARTERIOLES INVITRO
    EDWARDS, RM
    TRIZNA, W
    FEUERSTEIN, G
    JOURNAL OF LIPID MEDIATORS, 1991, 3 (02): : 161 - 165
  • [30] PATHOPHYSIOLOGY OF ACUTE-PANCREATITIS - THE ROLE OF PLATELET-ACTIVATING-FACTOR (PAF-ACETHER)
    AIS, JG
    NOVO, C
    GOMEZGARRE, M
    LOPEZFARRE, A
    LOPEZNOVOA, JM
    ROMEO, JM
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1992, 81 (01) : 25 - 28